Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether combination therapy with bevacizumab
(Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with
locally advancing or metastatic melanoma.